Esophageal Varices

This review synthesizes clinical evidence on belapectin, a galectin-3 inhibitor, highlighting its potential to reduce the incidence of esophageal varices in patients with MASH-related cirrhosis and portal hypertension, particularly at the 2 mg/kg dosage.